TNXP Tonix Pharmaceuticals Holding Corp.

-0.04  -2%
Previous Close 1.96
Open 1.99
Price To Book 0.34
Market Cap 4590983
Shares 2,391,137
Volume 128,967
Short Ratio
Av. Daily Volume 433,114

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial halted due to insufficient efficacy - July 27, 2018.
TNX-102 SL (Tonmya)
Post-traumatic stress disorder (PTSD)
Phase 2 data released February 2016 did not meet primary endpoint
Episodic tension-type headache
Phase 3 data released September 6, 2016. Primary endpoint not met. Program discontinued
TNX-102 SL
New Phase 3 trial to be initiated 1Q 2019 with data due 1H 2020.
Post-traumatic stress disorder (PTSD)

Latest News

  1. Tonix Pharmaceuticals Announces New Board Member, James Treco
  2. How Many Insiders Bought Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares?
  3. Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference
  4. TNXP: Additional Details Revealed for Phase 3 Trial of TNX-102 SL in PTSD Starting in 1Q19…
  5. Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
  6. Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
  7. Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering
  8. Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today
  9. Tonix Pharmaceuticals Prices $15,000,000 Public Offering
  10. Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target
  11. Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
  12. Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
  13. Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results
  14. TNXP: Ready to Initiate Phase 3 Trial of TNX-102 SL in PTSD in 1Q19…
  15. Tonix: 3Q Earnings Snapshot
  16. Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and ACADIA Pharmaceuticals